Chongqing Haisco Pharmaceutical Group Deal History & Licensing Activity
Chongqing Haisco Pharmaceutical Group is a life sciences. Over the past three years, Chongqing Haisco Pharmaceutical Group has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Option Deals
Chongqing Haisco Pharmaceutical Group Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Chongqing Haisco Pharmaceutical Group in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| dual PDE3/4 inhibitor | Haisco | Small Molecules | Phase 2 | license | Jun 12, 2026 |
| Multi-program collaboration (5 programs) | Eli Lilly | Small Molecules | Discovery | collaboration | May 15, 2026 |
Chongqing Haisco Pharmaceutical Group Pipeline Focus
Therapeutic areas and modalities where Chongqing Haisco Pharmaceutical Group is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Chongqing Haisco Pharmaceutical Group's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Chongqing Haisco Pharmaceutical Group Licensing & Deal Activity
Chongqing Haisco Pharmaceutical Group is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Chongqing Haisco Pharmaceutical Group ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Chongqing Haisco Pharmaceutical Group include Option Deals (2 deals and trials), Mega Deals (2 deals and trials), and Codev Deals (1 deal and trial). In terms of modality, Chongqing Haisco Pharmaceutical Group has shown particular interest in small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Chongqing Haisco Pharmaceutical Group and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Chongqing Haisco Pharmaceutical Group's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.